Hansa Biopharma to host conference call to provide interim results for the first nine months of 2019 and business update

Lund October 11, 2019. Hansa Biopharma will publish its interim report for the first nine months of 2019 at 8:00 a.m. CET on October 31, 2019. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 1:00 p.m. CET. The event will be hosted by Hansa Biopharma’s CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under “Events & Webcast,” and will also be made available online after the call. To participate in the telephone conference, please use the dial-in details provided below:

Dial-in numbers for participants:
SE: +46 8 566 42 661
UK: +44 203 19 40 544
US: +1 855 26 92 604

For additional international numbers, please refer to the complete list on https://livehouseeurope.com/telco_price/#tab-62e38f57f1bfadb16f0.

The webcast will be available on https://hansa.eventcdn.net/2019q3/.

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com

Rolf Gulliksen, Head of Corporate Communications
Hansa Biopharma
Mobile: +46 (0) 733-328 634
E-mail: rolf.gulliksen@hansabiopharma.com

About Hansa Biopharma
Hansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The Company’s lead product, imlifidase, is a unique antibody-degrading enzyme to enable kidney transplantation in highly sensitized patients with potential for further development in other solid organ transplantation and acute autoimmune indications. Imlifidase is currently under potential marketing authorization by EMA. Hansa’s research and development program is advancing the next generation of the Company’s technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in the UK and US.